displays the mean differences of the dose metrics between repeated CT and CBCT, for Varian and Elekta CBCT scans. For Varian, a good agreement between the dose distributions recalculated on CBCT and repeated CT was observed when a thorax-specific HU-ED table was used. For Elekta, the dose metrics showed larger deviations with the thorax-specific HU-ED table, however, using a patientspecific HU-ED table resulted in similar accuracy as for Varian CBCT dose calculations. Differences between repeated CT and CBCT dose metrics were below 3% for both vendors.
Purpose or Objective: At our department, patients with cT1-2aN0M0 laryngeal cancer are treated with volumetricmodulated arc therapy (VMAT). The treatment plan quality is monitored by plan evaluations on weekly repeat CTs. The purpose of this study was to determine plan quality during treatment by recalculating the actually given dose based on repeat CT. Material and Methods: Three patients treated with accelerated radiotherapy (66-70 Gy in 2 Gy fractions) were selected because of over dosages exceeding 78 Gy at the transition from air to tissue. Each clinical VMAT plan (plan I) was optimized towards homogeneous dose distributions in the planning target volumes (PTV) and low as possible dose to the critical organs such as the swallowing organs at risk. The treatment plan quality was evaluated using weekly repeat CTs. In addition, two more treatment plans were made including a density override of 0.5 g.cm-3 for the PTV-in-air overlap region (plan II), and the PTV-in-air + 5 mm region (plan III). All plans were evaluated with the PTV-in-air region assigned a density override value of 0.0 and 1.0 g.cm-3 to simulate the initial planning scenario and to simulate extension of CTV-in-air, resp. Finally, the "actual given dose" of the clinical target volume (CTV) was estimated by accumulated repeat CT dose evaluations.
Results:
The repeat CTs showed an extending CTV towards the laryngeal air cavity over the course of treatment. Repeat CT evaluations indicated increasing max doses up to 80 Gy. Evaluation of plan I on the initial planning CT, using a density override of 1.0 g.cm-3, showed a potential dose hotspot with similar max dose values (80-87 Gy). When no density override was assigned the PTV (D98%) coverage of plan I was sufficient. In contrast, plan II and III showed slightly to moderate PTV under dosage (65 Gy), albeit within the PTVin-air region. However, the accumulated CTV dose (D100) demonstrated no clinically relevant under dosage in the CTV (methods plan II: 67.4 Gy and plan III 65.2 Gy). Furthermore, the plan optimization approach as used in plan II and III resulted in reduced and acceptable max dose values within the targets (76.9 Gy and 74.3 Gy, resp).
Conclusion:
Unacceptable high doses of up to 80 Gy were observed in VMAT plan evaluations based on weekly repeat CTs. To avoid these over dosages, high fluence profiles in PTV-in-air regions should be avoided during planning optimization. An alternative VMAT optimization and evaluation approach has been proposed for cT1-2aN0M0 laryngeal cancer patients.
EP-1813
Clinical implementation of an adaptive planning technique for lung VMAT radiotherapy M. Naisbit Purpose or Objective: At the Leeds Cancer Centre approximately 40% of lung patients receiving VMAT radiotherapy (RT) display a reduction in tumour volume when imaged using CBCT during treatment. The aim of this work was to develop a method to assess whether the dosimetric impact of observed anatomical changes is sufficiently significant to justify a treatment replan.
Material and Methods:
Twelve lung patients receiving FFF VMAT RT planned on the Monaco 3.3 treatment planning system (Elekta) were identified. All had been rescanned, recontoured and replanned due to noted tumour shrinkage. For lung replans the clinical aim is to continue treating the original target volumes, so a rigid registration was performed between the planning CT and the rescan CT using a mutual information algorithm. Target volumes and OAR were transferred from the planning CT to the rescan CT and assessed by a physicist and clinician team to ensure they were clinically appropriate. The original plan was recalculated on the rescan CT studyset and dose volume histogram (DVH) statistics calculated for targets and OARs on the rescan studyset.
Results: For patients who displayed tumour changes without other significant internal changes the transferred target structures were deemed clinically acceptable with minor editing. Comparison of the transferred structures to the replan structures indicated that differences in remarking the targets were larger than image registration and transferral errors. Small variations in spinal cord and lung contours suggest that it is more accurate to re-contour these structures on the rescan CT, especially if they are receiving a dose close to tolerance. This method of adaptive planning was found to significantly reduce the replanning time. A notable limitation of the process was observed for patients who display other significant internal anatomical changes such as a change in lung volume or mediastina position, resulting in inaccurate transferred structures. Based on the DVH statistics for the transferred targets and re-contoured OAR, 9/12 plans required a full treatment replan. Although the target coverage was clinically acceptable the loss of tumour tissue meant that nearby OAR received doses above their tolerance.
________________________________________________________________________________

Conclusion:
A method has been developed to assist the adaptive planning process for lung patients receiving FFF VMAT radiotherapy. This provides a means of assessing the dosimetric effect of tumour changes to determine whether a new treatment plan is necessary. It showed that for 25% of patients who received full treatment replans no replan was necessary, as the dosimetric effect of tumour shrinkage was insignificant in terms of both target coverage and OAR doses. Therefore it allows significant time savings in the treatment replanning process. Use of the technique is limited to patients who display tumour volume changes with no other significant changes to internal/external anatomy.
EP-1814
Fractionated stereotactic radiotherapy using Gamma Knife Icon with adaptive re-planning (a-gkFSRT) F. Stieler Purpose or Objective: The Gamma Knife Icon (Elekta AB, Schweden) allows frameless treatment of patients in a precise stereotactic environment using a combination of cone-beam computer tomography (CBCT) for positioning, a thermoplastic mask system for positioning and fixation and an infrared based camera system "high definition motion management" (HDMM) for patient tracking during treatment. Using these novel options, the Gamma Knife Icon provides the possibility for adaptive fractionated stereotactic radiotherapy (a-gkFSRT). Here we report the treatment of the first patient with a-gkFSRT.
Material and Methods:
The first patient treated with Gamma Knife Icon at the University Medical Center Mannheim received MR imaging with an individual cushion for preplanning with the treatment planning system (TPS) GammaPlan 11.0.1 (Elekta AB, Schweden) 7 days before treatment. For every fraction of the treatment a daily CBCT was performed to verify the actual scull/tumour position. An automatic co-registration was performed to determine the daily shift in translation and rotation. The TPS adapted automatically the shot positions to the daily position and recalculated the dose distribution (online adaptive planning). During the treatment the HDMM system recorded the intrafractional patient motion. Further we recorded the times for positioning, image guidance and treatment to define a clinical treatment slot.
Results:
The total treatment time for fraction 2-5 was around 20 minutes. The positioning of the patient needed 0.8 min, CBCT positioning plus acquisition 1.03 min plus 0.62 min, CT data processing and adaptive planning 2.66 min and treatment 15.6 minutes. The mean values and standard deviations for the 5 daily CBCTs compared to the reference scan are for rotation -0.59°±0.49/0.18±0.20/0.05°±0.36 and for translation are 0.94mm±0.52/-0.08mm±0.08/-1.13mm±0.89. The adaptive re-planning (duration 1.25 minutes) every day was very accurate and yielded quality measures e.g. coverage, selectivity and gradient for the delivered dose identical regarding to the initial values. Using the HDMM system over all fractions we saw an intra-fractional movement of 0.13±0.04mm. The intra-fractional movement was controlled by the HDMM system and showed similar results as a repeated CBCT after treatment (<0.32° and 0.20mm).
Conclusion:
The Gamma Knife Icon allows combining the accuracy of the stereotactic Gamma Knife system with the flexibility of fractionated treatment of a linear accelerator with mask system and CBCT. Further the Icon system introduces a new online patient tracking system to the clinical routine. The inter-fractional accuracy of patient positioning was controlled with a thermoplastic mask and CBCT. The adaptive re-planning was quick and yielded high quality plans. Identical dose was delivered each day because of adaptive re-planning. Purpose or Objective: The aim of this study was to report the results of the validation of a previously developed method for dose of the day calculation in head and neck Tomotherapy based on deformable image registration (DIR) of the planning CT to MVCT taken during treatment.
Material and Methods: kVCT/MVCT images of ten HN patients treated with Helical Tomotherapy (HT) with a simultaneous integrated boost (54/66/69 Gy/30 fr) were retrospectively analyzed. For each patient the planning kVCT (CT-plan) was elastically registered (DIR) to the MVCT acquired at the 15th therapy session (MVCT15) with a B-Spline deformation algorithm using Mattes mutual information (open-source software 3D Slicer), resulting in a deformed CT (CTdef). At the same day, a kVCT was acquired with the patient in the same treatment position (CT15) and taken as reference. Then, CTdef and CT15 were re-sampled to the same slice thickness (3mm) through linear interpolation. The original HT plans were recalculated both on CTdef and CT15 in the HT planning station using the DQA (dose quality assurance) module, considering the two set of images as phantoms: images were rigidly aligned with the CT-plan, mimicking the true daily repositioning. Dose distributions on CTdef and CT15 were compared in order to assess the reliability of the method; local dose differences <2% of the prescribed dose (DD2%) and global gamma-index values (2%-2mm; considering points with dose >20% of the prescribed one) were assessed for all the available transversal slices (step: 6 mm) with Mapcheck SNC Patient Software (Sun Nuclear).
Results:
The results of DIR was qualitatively satisfactory when comparing CTdef against CT15. On average, 94.4% ± 0.9% of points passes the gamma analysis test and 87.9% ± 1.1% of the body's voxel were found for DD2% (on average 27 slices available for each patient). If excluding 3 patients where a relevant number of slices were cut due to the narrow FOV of the MVCT15, the values further improved to 95.7% ± 0.8% and 89.1% ± 1.3% for gamma and DD2% respectively.
Conclusion: CT to MVCT DIR using an open source system was proven to be an accurate method for calculating the dose of
